A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Latest Information Update: 28 May 2025
At a glance
- Drugs VX-264 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 21 May 2025 Planned End Date changed from 1 May 2026 to 29 May 2026.
- 21 May 2025 Planned primary completion date changed from 1 May 2026 to 29 May 2026.
- 21 May 2025 Status changed from recruiting to active, no longer recruiting.